Board summary
Key figures
42,940
Registered population
52.0% aged 18–64
32.0%
Aged 65+
ICB 21.9% · England 17.9%
3.3%
Ethnic minority (non-White)
0.9% Asian · England 9.6%
6.3%
In IMD quintile 1
ICB 9.2% · England 21.0%
~2,556
Core20 residents (est.)
Resident basis; registered basis ~2,787 · see page 3
9,143
Hypertension register
+5.83% in 3 yrs · England +5.60%
392
SMI register
35.2% of Rother's
998
COPD register
Reviews +13.20% in 3 yrs
Forecast to 2030
10,441
Hypertension patients, 2030
+1,298 on today
69.7%
QRISK ≥20% on statins, 2030
+4.33pp over 3 yrs
7.8%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Hypertension blood pressure control exceeds national average.
Hypertension treatment to target is 72.1% (+5.8 pp over 2023 to 2025), above Rother (69.2%), NHS Sussex ICB (69.1%) and England (70.3%).
Secondary prevention statin therapy trails England.
Statin treatment in diabetes with CVD history fell 2.2% over 2023 to 2025 to 80.6% (England 84.4%, +1.0%); QRISK ≥ 20% therapy is 60.0%.
Core20 deprivation concentrated in two practices.
Ferry Road Health Centre has 28.2% Core20 patients; Rye Medical Centre has 23.2%; Martins Oak, Fairfield, and Sedlescombe & Westfield Surgeries record 0.0%.
Population, age and ethnicity
Of 42,940 registered patients, 32.0% are aged 65+, alongside 20 catchment care homes
Rural Rother PCN serves 42,940 registered patients across its member practices. Older adults represent 32.0% of the list (13,741 patients aged 65+), above Rother (30.4%), NHS Sussex Integrated Care Board (21.9%), and England (17.9%). Working-age adults (18-64) form 52.0% (Rother 53.6%, ICB 60.5%, England 62.7%) and children aged 0-17 comprise 16.0% (Rother 16.1%, ICB 17.7%, England 19.6%). Based on Census usual residents rather than registered patients, 96.7% are White (Rother 95.6%, ICB 91.0%, England 81.1%), with an ethnic minority share of 3.3%. List size is projected to grow 1.7% to 2030 (Rother 2.0%, ICB 2.1%, England 2.3%; unverified methodology).
Age profile
65+: ICB 21.9%, England 17.9%
Ethnicity
Older people · falls rows are Rother local-authority (LA) data, not PCN
| Measure | Local | South East | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Rother LA) | 2,294 | 2,018 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 86.3% | 82.2% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 59.3% | 57.8% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Rother LA) | 1,159 | 981 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Rother LA) | 8.4 | 14.0 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 deprivation is 6.3% overall but concentrated entirely in two practices
Rural Rother PCN's Core20 share is 6.3%, below Rother (13.8%), NHS Sussex Integrated Care Board (9.2%), and England (21.0%), with an average IMD decile of 4.7 (England 5.5). Deprivation is concentrated in two practices: Ferry Road Health Centre records a 28.2% Core20 share (1,089 estimated patients) and Rye Medical Centre records 23.2% (1,698 estimated patients). The other five practices each record 0.0%. Inequalities outreach may achieve greater impact by prioritising Rye Medical Centre by patient volume and Ferry Road Health Centre by deprivation concentration.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
392
SMI register
0.91% recorded prevalence
248
Learning disability register
0.57% recorded prevalence
20
Care homes, 587 beds
In the PCN catchment
9.9%
Provide unpaid care
Rother, Census 2021
The PCN records 392 patients with severe mental illness (0.9%, Rother 1.2%) and 248 with learning disabilities (0.6%, Rother 0.7%), alongside 20 catchment care homes (587 beds). Rother records 12 rough sleepers in 2025 and a 9.9% unpaid care rate; borough figures are not PCN headcounts. Crude register rates trailing borough benchmarks may reflect demographic differences or recording practices, which register audits could test.
Severe mental illness: physical health checks
Recorded severe mental illness prevalence is 0.9% (England 1.0%). For physical checks, blood pressure reached 85.0% (England 83.4%, Rother 86.9%) and BMI reached 83.8% (England 82.1%, Rother 86.2%), while alcohol recording reached 87.5% (England 81.8%).
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
9,143
Hypertension register
+5.83%
Register growth, 3 yrs
Rother +3.70% · England +5.60%
+5.86pp
BP control, under 80
≤140/90 · +4.68pp aged 80+
+1,298
More patients by 2030
Forecast 10,441 (23.72%)
Hypertension case-finding and control
Hypertension prevalence is 21.2% (9,143 patients), above England (15.2%) and NHS Sussex Integrated Care Board (16.3%) but below Rother (22.0%). Register prevalence rose 1.2 pp (+5.8%) over three years (England +0.8 pp, +5.6%). Treatment to target is 72.1% (+5.8 pp over three years), outperforming England (70.3%) and Rother (69.2%). However, recent blood pressure recording is 88.6%, behind England (90.0%) and the ICB (90.2%). Practice prevalence spans from 17.6% at Northiam Surgery and 17.7% at Oldwood Surgery to 24.8% at Rye Medical Centre; crude rates are not age-adjusted. Clinical control exceeds national benchmarks; lower register prevalence relative to the borough could reflect demographic differences or case-finding variation, which audit across practices would test.
Lipids and statins
Statin treatment in diabetes with cardiovascular disease history fell 1.8 pp (England +0.8 pp) to 80.6%, trailing England (84.4%). Lipid-lowering therapy for QRISK ≥ 20% is 60.0%, below England (63.6%) and matching the ICB (60.0%). Fewer high-risk patients receive lipid therapy than national benchmarks imply, indicating an opportunity to prioritise secondary prevention recall audits.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 129,656 | £2.90 | £2.42 | £1.86 | £376,002 |
| Cardiovascular (all), 2025 | 159,660 | £4.00 | £3.32 | £3.33 | £638,640 |
In 2026, lipid-modifying drugs cost £2.90 per item across 129,656 items, exceeding England (£1.86) and NHS Sussex Integrated Care Board (£2.42), costing £134,842 more than at England's unit cost; unit costs do not establish prescribing inefficiency. Prescribing unit costs exceed benchmarks, pointing to an opportunity to review lipid-modifying drug choices alongside clinical review.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+6.25%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+2.83%
Asthma prevalence, PCN 3-yr % change
Asthma prevalence is 7.0% (2,907 patients), above England (6.6%) and below Rother (7.2%). Annual asthma review coverage is 62.9% (England 65.7%, Rother 59.1%), leaving about 1,100 patients without a recorded review. Prescribing for ages 5-19 reaches 2,213 items per 1,000 (England 1,488; ICB 1,553). Conversely, COPD review coverage reached 80.0% (England 76.4%) across 998 register patients (2.3% prevalence). Elevated youth prescribing alongside review shortfalls could reflect poor control; clinical audit of pediatric reviews would test this.
Cancer register and children's immunisation
Cancer QOF prevalence is 6.2% (2,690 patients), compared to England (3.8%) and NHS Sussex Integrated Care Board (4.7%). In childhood immunisation coverage, 6-in-1 uptake at 12 months is 88.9% (distance to 95% coverage target: -6.1 pp) and MMR dose 1 coverage at 24 months is 89.6% (distance to 95% coverage target: -5.4 pp).
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
58.5%
Sussex ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~1,360
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Sussex ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Prostate | 56.6% | 53.2% | 19% | 1,668 |
| Breast | 86.1% | 85.4% | 23% | 1,400 |
| Bowel | 49.8% | 47.0% | 26% | 1,133 |
| Lung | 30.3% | 33.8% | 15% | 1,058 |
| Skin cancer | 95.3% | 87.8% | 17% | 698 |
In 2022, 58.5% of cancers with a known stage in NHS Sussex ICB were diagnosed at stage 1 or 2 (4,799 of 8,209 cases), exceeding England (55.3%) but sitting 16.5 percentage points below the 75.0% national ambition by 2028. Reaching the ambition would require about 1,360 additional early diagnoses annually across the ICB. Staging completeness was 64.3% (England 67.0%). In primary care, PCN cervical screening coverage in ages 25-49 is 72.6% (England 66.8%), after a 1.6% three-year decline (England -1.0%). Coverage is 69.1% at Northiam Surgery and 70.4% at Ferry Road Health Centre. Staging metrics reflect system pathways, not PCN performance.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In July 2026 (provisional), East Sussex Healthcare NHS Trust achieved 84.2% on the cancer 28-day faster diagnosis standard, exceeding the 75.0% standard, NHS Surrey and Sussex Integrated Care Board (79.3%), and England (79.3%). On the 62-day referral to treatment standard, East Sussex Healthcare NHS Trust reached 67.0%, below the 85.0% standard by 18.0 pp, trailing England (71.2%) and the ICB (71.5%). Acute trust waiting times reflect secondary care operational capacity rather than primary care performance.
| Pathways within standard (%) | East Sussex Healthcare | Maidstone and Tunbridge Wells | East Kent | Surrey and Sussex ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 84.20 | 81.78 | 71.28 | 79.29 | 79.32 |
| 31-day treatment (96%) | 98.19 | 98.35 | 96.67 | 90.45 | 92.50 |
| 62-day referral to treatment (85%) | 67.04 | 87.43 | 70.01 | 71.51 | 71.16 |
| Diagnostic waits over 6 weeks (%) | East Sussex Healthcare | Maidstone and Tunbridge Wells | East Kent | England |
|---|---|---|---|---|
| MRI | 6.48 | 0.92 | 47.58 | 21.40 |
| CT | 0.48 | 0.51 | 37.45 | 9.92 |
| Echocardiography | 21.94 | 2.57 | 14.17 | 28.48 |
| Colonoscopy | 0.74 | 19.80 | 9.58 | 30.83 |
| Gastroscopy | 0.31 | 24.03 | 22.16 | 29.02 |
| All 15 DM01 tests | 5.27 | 6.42 | 48.38 | 23.14 |
| Community services activity | East Sussex residents | Surrey and Sussex ICB |
|---|---|---|
| Care contacts | 100,740 | 309,615 |
| Referrals | 17,285 | 66,930 |
| Patients with a contact | 25,880 | 85,660 |
Community services (residents of East Sussex), Jun 2026 (provisional). In June 2026 (provisional), community service activity recorded 100,740 total contacts with Rother residents, of which 68,465 (68.0%) were with adults aged 65+. These borough-level figures reflect older-age community caseloads across the local authority, although activity for registered PCN patients was not captured.
Practice variation and patient experience
Practice variation and patient experience
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Northiam Surgery | 126 | 0.0 | 99.3% | 79.7% | 99.3% |
| Oldwood Surgery | 121 | 0.0 | 93.2% | 86.4% | 97.6% |
| Martins Oak | 121 | 0.0 | 86.0% | 79.3% | 93.5% |
| Fairfield Surgery | 102 | 0.0 | 84.1% | 68.2% | 88.4% |
| Rye Medical Centre | 124 | 23.2 | 87.4% | 82.7% | 88.3% |
| Ferry Road | 109 | 28.2 | 63.2% | 63.8% | 87.2% |
| Sedlescombe & | 116 | 0.0 | 61.3% | 78.5% | 80.6% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Three-year register growth trailed England in learning disability and dementia
Three-year register growth trailed England in learning disability (+1.8% vs +5.4%) and dementia (+2.7% vs +6.0%). For diabetes patients with prior CVD, statin treatment fell 2.2% (England +1.0%). In contrast, three-year improvements exceeded England in smoking cessation offers (+10.7 pp vs +0.1 pp), COPD reviews (+13.2% vs +2.8%), and alcohol checks in psychosis (+14.6 pp vs +5.4 pp). Slower register expansion and declining statin use could reflect unmet review needs, which local clinical audit would test.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Learning disability register
Dementia register
Diabetes statin (CVD)
Heart failure reviews
Diabetes HbA1c control
Smoking support (SMI)
COPD reviews
Alcohol record (psychosis)
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Rother | Asset | PCN | Rother |
|---|---|---|---|---|---|
| Care homes (catchment) | 20 (587 beds) | n/a | Schools (catchment) | 58 | n/a |
| Children's centres | 1 | 2 | Places of worship | 71 | 103 |
| Libraries | 2 | 3 | Food banks (VCS) | 2 | 3 |
| Homelessness support (VCS) | 0 | 2 | Day centres (VCS) | 22 | 26 |
| Children and young people (VCS) | 5 | 6 | Primary schools (LA maintained) | 23 | 23 |
| Primary academies | 5 | 9 | Special schools | 1 | 2 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Structured asthma review and prescribing audit
Annual asthma review coverage is 62.9% (England 65.7%, Rother 59.1%) across 2,907 register patients (about 1,100 without a recorded review), while prescribing in ages 5-19 is 2,213 items per 1,000 (England 1,488). Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
Secondary prevention lipid recall and review
Statin therapy in diabetes with CVD fell 2.2% (England +1.0%) to 80.6% (England 84.4%) and lipid therapy for QRISK ≥ 20% is 60.0% (England 63.6%); lipid-modifying prescribing costs £2.90 per item (England £1.86), or £134,842 more than at England's unit cost across 129,656 items. Moderate effort to run.
Evidence base: delivery measure for eight care processes and three treatment targets; shortfall here is what shows up later as emergency admission.
Policy anchor: NHS Diabetes Prevention Programme and the eight care processes / three treatment targets.
Option 3
Dementia and learning disability register validation
Three-year register growth trailed England in dementia (+2.7% vs +6.0%; prevalence 0.9% vs Rother 1.3%, modelled range -74 to +164 across 410 patients) and learning disability (+1.8% vs +5.4%; 0.6% vs Rother 0.7%, range +4 to +40 across 248 patients). Moderate effort to run.
Evidence base: the register is the cohort for the annual health check and LeDeR learning; people with a learning disability die on average 20 years earlier and are a Core20PLUS5 PLUS group.
Policy anchor: annual health checks for 75% of people aged 14+ on the register (Network Contract DES); Oliver McGowan mandatory training.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Older population multidisciplinary care planning (p2) | Aged 65+ | Neighbourhood health framework · NHS vaccination strategy | PCN |
| Targeted Core20 practice outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| Physical health check recall (p4) | SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
| Hypertension case finding review (p5) | Hypertension: QOF prevalence | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Preschool immunisation recall audit (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening recall audit (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Telephony and triage workflow review (p9) | GPPS good overall experience of the practice | 10YHP, hospital to community | Practice |
| Option 1 · Structured asthma review and prescribing audit (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) · Asthma management items prescribed per 1000 5-19 Population | Core20PLUS5 respiratory | PCN & Practice |
| Option 2 · Secondary prevention lipid recall and review (p12) | Patients with diabetes and a history of CVD (excl. haem. stroke) treated with a statin (denominator incl. PCAs) · Patients with QRISK ≥ 20% treated with lipid lowering therapy · Cost per item for Lipid-regulating drugs 2026 | NHS Long Term Plan (diabetes) and National Diabetes Audit | PCN & Practice |
| Option 3 · Dementia and learning disability register validation (p12) | Learning disability register · Learning disability: QOF prevalence · Dementia register | 75% annual health checks (Network Contract DES) · Oliver McGowan · 66.7% diagnosis ambition · 95% care plan 2027 | PCN & Practice |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | ICB | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
